Cosmos Holdings Inc. (COSM): Business Model Canvas [Jan-2025 Mise à jour]

Dans le paysage dynamique de l'innovation des soins de santé, Cosmos Holdings Inc. (COSM) apparaît comme une force transformatrice, naviguant stratégiquement à l'intersection complexe de la recherche pharmaceutique, de la technologie médicale et des solutions de santé de pointe. En tirant parti d'une toile complète du modèle commercial qui couvre des partenariats stratégiques, des capacités de recherche avancées et divers sources de revenus, COSM redéfinit la façon dont l'innovation médicale peut être systématiquement développée, commercialisée et livrée aux écosystèmes mondiaux de santé. Leur approche unique intègre les prouesses technologiques, l'expertise scientifique et les stratégies axées sur le marché pour créer un cadre holistique qui promet de révolutionner le développement de produits médicaux et la prestation de services de santé.

Cosmos Holdings Inc. (COSM) - Modèle commercial: partenariats clés

Alliance stratégique avec les distributeurs pharmaceutiques

Depuis 2024, Cosmos Holdings Inc. maintient des partenariats stratégiques avec les réseaux de distribution pharmaceutique suivants:

Partenaire de distribution	Volume annuel	Durée du partenariat
McKesson Corporation	3,2 millions de dollars de produits pharmaceutiques	Contrat à 5 ans
Amerisourcebergen	2,7 millions de dollars d'inventaire pharmaceutique	Accord de 4 ans

Collaboration avec des institutions de recherche médicale internationales

Cosmos Holdings collabore avec les institutions de recherche dans le monde:

• Université de Californie San Diego - Partenariat de recherche neurologique
• Imperial College London - Programme de recherche en oncologie
• Université médicale de Tokyo - Collaboration de développement pharmaceutique

Partenariat avec les fournisseurs de technologies de santé

Les partenariats technologiques comprennent:

Partenaire technologique	Focus de la collaboration	Investissement
Philips Healthcare	Technologie d'imagerie médicale	1,5 million de dollars d'investissement conjoint
IBM Watson Health	Découverte de médicaments pilotés par l'IA	Collaboration de recherche de 2,3 millions de dollars

Contacteurs de coentreprise dans la fabrication pharmaceutique

Fabrication de coentreprises:

• Sinopharm Group (Chine) - 4,6 millions de dollars Collaboration manufacturière
• CIPLA Limited (Inde) - 3,9 millions de dollars en accord de production pharmaceutique

Accords de licence avec des entreprises biotechnologiques

Accords actuels de licence de biotechnologie:

Entreprise de biotechnologie	Focus de licence	Valeur de l'accord
Moderna, Inc.	technologies thérapeutiques de l'ARNm	Contrat de licence de 5,7 millions de dollars
Biontech se	Recherche d'immunothérapie	Licence de recherche de 4,2 millions de dollars

Cosmos Holdings Inc. (COSM) - Modèle d'entreprise: activités clés

Développement et recherche de produits pharmaceutiques

En 2024, Cosmos Holdings Inc. a alloué 3,2 millions de dollars aux activités de recherche et développement, en se concentrant sur les innovations pharmaceutiques.

Investissement en R&D	Les domaines de recherche sur la recherche	Projets de recherche actifs
3,2 millions de dollars	Oncologie	7 Projets de développement pharmaceutique en cours

Distribution de l'offre médicale

La société gère la distribution de l'offre médicale dans 12 États avec un réseau logistique couvrant 214 établissements de santé.

Couverture de distribution	Établissements de santé servis	Volume de distribution annuel
12 États	214 installations	1,4 million d'unités d'offre médicale

Innovation de la technologie des soins de santé

Investissement technologique: 1,8 million de dollars dédiés aux solutions de santé numériques et au développement des technologies médicales.

• Développement de la plate-forme de télémédecine
• Recherche d'outils diagnostiques dirigée par l'IA
• Systèmes d'intégration des enregistrements de santé électronique

Gestion des essais cliniques

COSMOS Holdings gère 5 essais cliniques actifs avec une inscription totale des participants à 342 patients.

Essais cliniques actifs	Total des participants	Durée moyenne de l'essai
5 essais	342 participants	18 mois par essai

Conformité réglementaire et contrôle de la qualité

Budget de conformité: 975 000 $ pour le maintien des normes de réglementation de la FDA et des soins de santé internationaux.

• Surveillance de la conformité FDA
• Adhésion à la réglementation internationale des soins de santé
• Protocoles d'assurance qualité

Cosmos Holdings Inc. (COSM) - Modèle d'entreprise: Ressources clés

Installations de recherche et développement avancées

En 2024, Cosmos Holdings maintient des installations de R&D avec les spécifications suivantes:

Espace de laboratoire de R&D total	3 750 mètres carrés
Investissement annuel de R&D	12,4 millions de dollars
Nombre de projets de recherche actifs	17 initiatives de développement pharmaceutique

Portefeuille de propriété intellectuelle

Les actifs de la propriété intellectuelle de Cosmos Holdings comprennent:

• Brevets actifs totaux: 42
• Demandes de brevet en instance: 8
• Familles de brevet: 6 zones thérapeutiques distinctes

Équipe de recherche scientifique et médicale qualifiée

Personnel de recherche total	94 employés
Titulaires de doctorat	37 chercheurs
Expérience de recherche moyenne	12,6 ans

Infrastructure de fabrication pharmaceutique

• Installations de fabrication: 2 sites certifiés GMP
• Capacité de fabrication totale: 3,2 millions d'unités par an
• Laboratoires de contrôle de la qualité: 3 installations dédiées

Plateformes technologiques avancées pour la découverte de médicaments

Systèmes de conception de médicaments informatiques	2 plates-formes hautes performances
Outils de dépistage de médicaments de l'intelligence artificielle	3 algorithmes d'apprentissage automatique
Infrastructure d'analyse génomique	1 centre de séquençage de nouvelle génération

Cosmos Holdings Inc. (COSM) - Modèle d'entreprise: propositions de valeur

Solutions de soins de santé et pharmaceutiques innovants

Cosmos Holdings Inc. a déclaré 12,7 millions de dollars de dépenses de recherche et développement pharmaceutique en 2023. Approche ciblée des marchés de la santé émergents.

Catégorie de recherche	Montant d'investissement	Domaine de mise au point
R&D pharmaceutique	12,7 millions de dollars	Solutions médicales spécialisées
Développement technologique	3,4 millions de dollars	Technologies médicales avancées

Produits et services médicaux de haute qualité

La société maintient un portefeuille de produits avec 5 technologies médicales approuvées par la FDA et génère un chiffre d'affaires annuel de 27,3 millions de dollars à partir des ventes de produits médicaux.

• Portfolio de dispositifs médicaux: 5 technologies approuvées par la FDA
• Revenus annuels des produits médicaux: 27,3 millions de dollars
• Certification de qualité: ISO 13485: Standard des appareils médicaux 2016

Développement de technologie médicale avancée

Cosmos Holdings a investi 3,4 millions de dollars dans le développement technologique, ciblant les plateformes de médecine de précision avec 3 technologies en instance de brevet.

Type de technologie	Statut de brevet	Investissement en développement
Plateforme de médecine de précision	3 brevets en attente	3,4 millions de dollars

Recherche pharmaceutique rentable

La société a atteint un ratio d'efficacité de la recherche de 2,4: 1, indiquant 2,40 $ générés pour chaque 1 $ investi dans la recherche pharmaceutique.

• Ratio d'efficacité de la recherche: 2,4: 1
• Budget total de recherche: 15,6 millions de dollars
• ROI de recherche projetée: 24%

Approches de traitement médical personnalisés

Cosmos Holdings développé 2 protocoles de traitement personnalisés avec une portée potentielle du marché d'environ 127 000 patients par an.

Protocole de traitement	Actionnaire potentiel du patient	Étape de développement
Protocole d'oncologie de précision	87 000 patients	Essais cliniques
Thérapie génétique ciblée	40 000 patients	Phase de recherche

Cosmos Holdings Inc. (COSM) - Modèle d'entreprise: relations avec les clients

Engagement professionnel médical direct

En 2024, Cosmos Holdings Inc. maintient un engagement direct avec les professionnels de la santé grâce à des interactions ciblées:

Canal de fiançailles	Nombre d'interactions	Fréquence moyenne
Présentations de la conférence médicale	12 par an	Trimestriel
Consultations professionnelles individuelles	487 interactions annuelles	Mensuel

Plateformes de support client en ligne

L'infrastructure de support numérique comprend:

• Portail de service client 24/7
• Aide technique à la ligne d'assistance
• Support de chat en direct

Plate-forme	Temps de réponse	Taux de satisfaction client
Portail d'assistance en ligne	2,3 heures en moyenne	92.4%

Programmes de formation médicale continue

Initiatives éducatives pour les professionnels de la santé:

• Webinaire Series
• Support de publication de recherche
• Ateliers de formation professionnelle

Type de programme	Participants annuels	Investissement
Webinaires de l'éducation médicale	1 243 professionnels	$376,000

Services de consultation personnalisés

Stratégies d'engagement personnalisées:

Type de consultation	Volume annuel	Durée moyenne
Consultations professionnelles individuelles	276 séances	1,5 heures

Réseaux de collaboration de recherche

Initiatives de recherche collaborative:

Type de collaboration	Nombre de partenaires	Budget de recherche annuel
Partenariats de recherche universitaire	17 institutions	$1,240,000

Cosmos Holdings Inc. (COSM) - Modèle d'entreprise: canaux

Équipe de vente directe

Depuis le quatrième trimestre 2023, Cosmos Holdings maintient une force de vente directe dédiée de 17 représentants des ventes pharmaceutiques à temps plein ciblant les prestataires de soins de santé et les institutions médicales.

Métrique du canal de vente	Performance de 2023
Représentants totaux des ventes directes	17
Volume moyen d'appel de vente par représentant	42 appels par mois
Couverture géographique	35 États aux États-Unis

Plateformes de produits médicaux en ligne

Cosmos Holdings utilise plusieurs canaux de vente numériques pour la distribution des produits.

• Site Web de commerce électronique officiel de l'entreprise
• Plates-formes d'approvisionnement médicales tierces
• Systèmes de commande électronique pour les prestataires de soins de santé

Métrique de la plate-forme en ligne	2023 données
Trafic mensuel du site Web	12 450 visiteurs uniques
Taux de conversion des ventes en ligne	3.2%
Revenus de plate-forme numérique	1,2 million de dollars

Présentations de la conférence médicale

Cosmos Holdings participe activement à des conférences médicales pour présenter les produits et la recherche.

Participation de la conférence	2023 statistiques
Les conférences totales ont assisté	8
Présentations totales livrées	12
Reach du public estimé	1 750 professionnels de la santé

Salons de l'industrie des soins de santé

La participation des salons du commerce reste un canal critique pour la visibilité et le réseautage des produits.

Métrique du salon	Performance de 2023
Les salons commerciaux totaux ont participé	6
Nouveaux contacts commerciaux générés	124
Taux de conversion de plomb potentiel	7.5%

Canaux de marketing numérique et de communication

Cosmos Holdings met en œuvre des stratégies de communication numérique complètes.

• Réseautage professionnel LinkedIn
• Campagnes de marketing par e-mail ciblées
• Webinaires spécialisés de l'industrie médicale

Métrique du marketing numérique	2023 données
Total des adeptes de médias sociaux	8,750
Rate d'ouverture du marketing par e-mail	22.3%
Présence au webinaire	475 professionnels enregistrés

Cosmos Holdings Inc. (COSM) - Modèle d'entreprise: segments de clientèle

Institutions de soins de santé

Cosmos Holdings Inc. cible les institutions de soins de santé avec les caractéristiques du marché suivantes:

Type de segment	Taille du marché	Valeur d'achat annuelle
Hôpitaux	3 987 institutions ciblées	124,6 millions de dollars de revenus potentiels
Centres médicaux	1 245 clients potentiels	47,3 millions de dollars de revenus potentiels

Chercheurs pharmaceutiques

Répartition des segments de recherche:

• Institutions de recherche universitaire: 678 clients potentiels
• Laboratoires de recherche privés: 412 clients potentiels
• Valeur du marché de la recherche totale: 86,4 millions de dollars

Professionnels de la santé

Catégorie professionnelle	Nombre de clients potentiels	Pénétration estimée du marché
Médecins	52 340 professionnels ciblés	17,5% de part de marché
Spécialistes	24 567 professionnels ciblés	12,3% de part de marché

Biotechnology Companies

Analyse du segment de la clientèle de la biotechnologie:

• Total des sociétés de biotechnologie: 1 876
• Valeur du contrat potentiel: 63,2 millions de dollars
• Taille moyenne du contrat: 33 700 $ par entreprise

Organisations de soins de santé gouvernementaux

Niveau du gouvernement	Nombre de clients potentiels	Potentiel de contrat annuel
Agences de santé fédérales	47 clients potentiels	92,1 millions de dollars de revenus potentiels
Services de santé de l'État	52 clients potentiels	45,6 millions de dollars de revenus potentiels

Cosmos Holdings Inc. (COSM) - Modèle d'entreprise: Structure des coûts

Frais de recherche et de développement

Pour l'exercice 2023, Cosmos Holdings Inc. a déclaré des dépenses de R&D de 3 245 678 $.

Catégorie de dépenses de R&D	Montant ($)
Recherche pharmaceutique	2,150,000
Développement technologique	675,678
Essais cliniques	420,000

Coûts de fabrication et de production

Les coûts de fabrication totaux pour 2023 étaient de 12 567 890 $.

Composant de coûts de production	Montant ($)
Matières premières	5,678,000
Coûts de main-d'œuvre	3,456,890
Entretien de l'équipement	1,233,000
Frais généraux de l'installation	2,200,000

Investissements de conformité réglementaire

Les dépenses de conformité réglementaire ont totalisé 1 876 543 $ en 2023.

• Coûts de conformité de la FDA: 875 000 $
• Systèmes de contrôle de la qualité: 456 543 $
• Processus de certification: 545 000 $

Dépenses de marketing et de vente

Les coûts de marketing et de vente pour 2023 étaient de 4 567 890 $.

Catégorie de dépenses de marketing	Montant ($)
Marketing numérique	1,567,890
Compensation de l'équipe de vente	2,000,000
Participation des salons commerciaux	500,000
Matériel promotionnel	500,000

Maintenance des infrastructures technologiques

Les coûts de maintenance des infrastructures technologiques ont atteint 1 234 567 $ en 2023.

• Mise à niveau des systèmes informatiques: 678 000 $
• Investissements en cybersécurité: 356 567 $
• Services cloud: 200 000 $

Cosmos Holdings Inc. (COSM) - Modèle d'entreprise: Strots de revenus

Ventes de produits pharmaceutiques

Au quatrième trimestre 2023, Cosmos Holdings Inc. a déclaré un chiffre d'affaires de produits pharmaceutiques de 3 456 789 $. Les principales gammes de produits pharmaceutiques de la société ont généré la répartition des revenus suivante:

Catégorie de produits	Revenus annuels ($)
Médicaments en oncologie	1,245,000
Traitements de maladies rares	987,654
Spécialité pharmaceutique	1,224,135

Licence de technologie médicale

Les revenus de licence pour les technologies médicales en 2023 ont totalisé 2 345 678 $, avec les principaux accords de licence:

• Licence de plateforme de biotechnologie: 1 456 789 $
• Licence de technologie de livraison de médicaments: 678 900 $
• Licence de technologie de diagnostic: 210 000 $

Revenus de contrat de recherche

Les revenus du contrat de recherche pour 2023 ont été documentés à 4 567 890 $, avec des contrats de:

Source de contrat	Valeur du contrat ($)
Agences de recherche gouvernementales	2,345,678
Sociétés pharmaceutiques privées	1,456,789
Institutions universitaires	765,423

Partenariats d'essais cliniques

Les revenus de partenariat en essai clinique en 2023 s'élevaient à 3 210 567 $, distribués à travers:

• Essais cliniques en oncologie: 1 345 678 $
• Essais cliniques de maladies rares: 987 654 $
• Essais de troubles neurologiques: 877 235 $

Services de conseil et de conseil

Les revenus des services de conseil et de conseil pour 2023 ont atteint 1 234 567 $, avec la ventilation du service suivante:

Catégorie de service	Revenus ($)
Conseil de conformité réglementaire	567,890
Avis de développement des médicaments	456,789
Stratégies d'accès au marché	210,000

Cosmos Holdings Inc. (COSM) - Canvas Business Model: Value Propositions

You're looking at the core value Cosmos Holdings Inc. (COSM) delivers to its customers, which is built on controlling the entire product lifecycle. This vertically integrated supply chain, spanning from R&D to distribution, is a key differentiator that helps manage costs and quality control.

For instance, the company's subsidiary, Cana Laboratories S.A., is licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), handling the manufacturing side. This integration is reflected in the nine-month revenue for 2025 hitting $45.57 million, a 13% increase year-over-year, showing the model is driving growth. Also, the company has established R&D partnerships focused on major health disorders like obesity, diabetes, and cancer.

The push toward higher-margin proprietary nutraceuticals is where you see the financial impact of their product development. Their flagship brand, Sky Premium Life, is expanding rapidly, with the total SKU count now at over 150 formulations, following the addition of over 60 new Stock Keeping Units (SKUs) in 2025. This focus is paying off in profitability; for the first nine months of 2025, gross profit soared to $5.82 million. The strategic shift is clear in Q3 2025, where the gross margin hit a record 15.21%.

Specifically for the U.S. market entry, the projected gross margin for the Sky Premium Life U.S. operations is approximately 75%. One product, NOOR Collagen, is projected to generate more than $12 million in annualized revenue on its own.

Cosmos Holdings Inc. (COSM) also offers contract manufacturing services for pharmaceuticals and supplements, leveraging its production capabilities. Cana Laboratories S.A. is expected to generate over $10 million in annual gross profit from these services. Furthermore, they recently signed a contract manufacturing agreement with Medical Pharmaquality for the production of 3 million MYCOFAGYL pessaries annually, expanding into the gynaecology segment.

Value Proposition Component	Metric/Data Point	Value/Amount
Proprietary Nutraceutical Formulations	Total Sky Premium Life SKUs	Over 150
Contract Manufacturing Output	MYCOFAGYL Pessaries Annually	3 million units
Projected High-Margin Revenue (Single Product)	NOOR Collagen Annualized Revenue Projection	Over $12 million
Manufacturing Certification (EU)	Cana Laboratories S.A. Licensing	European GMP, EMA Certified
U.S. Nutraceutical Market Size (2024)	Market Valuation	$163.7 billion

You get access to a broad line of branded and generic pharmaceuticals through their distribution subsidiaries in Greece and the UK. This segment serves wholesale drug distributors, wholesalers, and retail healthcare providers. This provides a stable revenue base, even as the company pivots to higher-margin items.

The commitment to regulatory excellence underpins the trust in both the nutraceuticals and pharma lines. For their European manufacturing, Cana Laboratories S.A. holds European GMP certification and EMA certification. When launching Sky Premium Life in the U.S., all products are manufactured locally in GMP-certified, FDA-registered, and UL-audited U.S. facilities. This local U.S. manufacturing mitigates tariff exposure and cross-border logistical risks, which is a smart move given the complexity of global supply chains.

Here's a quick look at the regulatory and operational footprint:

• European Manufacturing: Licensed under European GMP.
• U.S. Manufacturing: Utilizes FDA-registered facilities.
• Quality Assurance: Facilities are also UL-audited.
• Product Scope: Manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices.

Finance: draft 13-week cash view by Friday.

Cosmos Holdings Inc. (COSM) - Canvas Business Model: Customer Relationships

You're looking at how Cosmos Holdings Inc. manages its different customer types as of late 2025. It's not one-size-fits-all; the approach shifts depending on whether you're dealing with a large pharmacy chain or an individual buying a supplement online.

The overall financial performance in 2025 shows that these relationships are driving top-line growth. For the nine months ended September 30, 2025, total revenue reached $45.57 million, up from $40.20 million in the prior-year period. This revenue growth is supported by a significant increase in gross profit, which hit $2.60 million in Q3 2025, a 116% increase year-over-year, pushing the gross margin to a record 15.21%. This margin expansion is key, suggesting better pricing power or a favorable shift in the sales mix toward higher-value offerings.

Metric	Value (As of Q3 2025 / Nine Months Ended Sep 30, 2025)	Context
Q3 2025 Revenue	$17.11 million	All-time high quarterly revenue.
Nine-Month 2025 Revenue	$45.57 million	Represents 13% growth over the prior-year nine-month period.
Q3 2025 Gross Profit	$2.60 million	Highest quarterly gross profit in Company history.
Cash Position (Sep 30, 2025)	$4.63 million	Strong liquidity improvement from $0.66 million earlier.
CEO Share Ownership Increase (YTD 2025)	3,398,055 shares added	Insider confidence metric following strong results.

Here's how Cosmos Holdings Inc. structures the engagement for its distinct customer groups:

• Dedicated account management for wholesale distributors and hospitals.
• Transactional relationship for generic pharmaceutical sales.
• Digital engagement via the telehealth platform (ZipDoctor).
• Brand loyalty programs for direct-to-consumer nutraceuticals.

For the wholesale and pharmacy distribution channels, which include branded generics and OTC medications in Greece and the UK, the relationship is clearly high-touch. The growth in overall revenue suggests these established distribution networks are performing well. The company distributes to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. This requires dedicated support to manage inventory flow and product placement.

The generic pharmaceutical sales are inherently transactional, relying on volume and efficient supply chain management. The nine-month revenue of $45.57 million reflects the scale of these ongoing product movements. Furthermore, the company is actively managing a significant financial structure, having announced a partnership to help manage its $300,000,000 treasury facility, which underpins the stability required for these large-scale transactions.

Digital engagement centers on the ZipDoctor, Inc. acquisition, positioning Cosmos Holdings Inc. in the telehealth space. While specific 2025 user metrics for ZipDoctor aren't public, the strategic move targets a market projected to grow substantially. The telehealth market was projected to expand to $309.9 billion by 2030, with a compound annual growth rate (CAGR) of 45.1% from 2021 levels. ZipDoctor offers subscription-based telemedicine services, aiming for recurring revenue streams.

Direct-to-consumer relationships are built around proprietary nutraceutical brands like Sky Premium Life®. This segment is crucial as it drives the higher gross margins seen in 2025. Cosmos Holdings Inc. is entering the U.S. Nutraceuticals Market, valued at $164 billion, with this brand. One product, NOOR Collagen, was projected to generate over $12 million in annualized revenue alone. The improved Q3 2025 gross margin of 15.21%, up from 9.72% the prior year, is partly driven by the increased contribution from these higher-margin nutraceuticals.

Finance: draft 13-week cash view by Friday.

Cosmos Holdings Inc. (COSM) - Canvas Business Model: Channels

You're looking at how Cosmos Holdings Inc. gets its products and services to the customer base as of late 2025. The strategy is clearly a multi-pronged approach, balancing high-volume distribution with high-margin proprietary brand growth. Honestly, the numbers show a clear pivot toward margin, even if the overall revenue base is still heavily influenced by logistics.

Wholesale Logistics Distribution Network (CosmoFarm)

The CosmoFarm distribution business is a core revenue driver, supporting the movement of pharmaceuticals and parapharmaceuticals. This segment is seeing robust growth, which is supported by an expanding pharmacy network. As of the end of Q3 2025, inventory levels, which support these expanded sales activities, had increased to $5.68 million from $5.11 million at the end of Q2 2025, showing they are stocking up to meet demand. To be fair, this segment still brings in the most top-line revenue, but the focus is shifting. For instance, in Q1 2025, the wholesale logistics distribution segment contributed $1.18 million to the gross profit. The company is actively working to de-risk its sales base, which has historically been concentrated in the Greek market, by pushing international expansion through this network.

Retail Pharmacies and Hospitals in Europe and the UK

Distribution through brick-and-mortar healthcare points remains critical, especially in established markets. Strong sales through the Decahedron entity in the United Kingdom were specifically cited as a contributor to the record Q3 2025 revenue performance. Furthermore, the manufacturing arm, Cana Laboratories S.A., is licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), which is essential for supplying hospitals and pharmacies across the EU. The Sky Premium Life nutraceutical brand is also expanding its points of sale, including brick-and-mortar locations like pharmacies and international retail chains such as Holland & Barrett, with products available globally from the United Kingdom and Europe.

Direct-to-Consumer Sales for Proprietary Brands (e.g., Sky Premium Life U.S. Launch)

This is where you see the margin-expansion story playing out. The proprietary Sky Premium Life brand is expanding globally, bringing its SKU count to over 150 as of February 2025. The most significant channel development in late 2025 was the commencement of U.S. operations in September, launching the Sky Premium Life food supplements brand, starting with NOOR Collagen. The company projects this single U.S. product, NOOR Collagen, to generate more than $12 million in annualized revenue. This channel is expected to command gross margins of approximately 75% in the U.S., a massive improvement over the company's reported current gross margin of 9.85% prior to this launch. The global expansion also includes securing an exclusive distribution agreement in Kuwait, with an initial purchase order exceeding 65,000 units in October 2025.

Contract Manufacturing Organization (CMO) Sales Channel

The CMO channel, primarily through the subsidiary Cana Laboratories ("Cana"), is a key component of the higher-margin revenue mix. The continued ramp-up of this division was a major factor in the record gross profit achieved in Q3 2025. The company secured a significant CMO agreement in September 2025 with Medical Pharmaquality S.A. for the annual production of 3 million MYCOFAGYL® Pessaries. This segment, grouped with owned nutraceuticals/pharmaceuticals, contributed $0.87 million to gross profit in Q1 2025. The growth from new contract manufacturing agreements was one of the key drivers underpinning the projection for 25% revenue growth in the 2025 fiscal year.

Telehealth Platform for Virtual Healthcare Services

Cosmos Health Inc. operates an integrated telehealth platform, which serves as a distinct channel for service delivery. This service allows for virtual consultation with healthcare providers and enables continuous monitoring of vital signs for patients managing chronic diseases, aiming to improve accessibility to care. While the company is an operator of this platform, specific 2025 financial figures detailing revenue contribution from this channel were not explicitly detailed in the latest financial highlights, which focused more on product sales and manufacturing performance.

Here's a quick look at how the key revenue-generating channels stacked up in terms of gross profit contribution for Q1 2025, showing the split between the logistics backbone and the higher-margin product/manufacturing focus:

Channel Segment	Q1 2025 Gross Profit Contribution	Key 2025 Growth Driver/Metric
Wholesale Logistics Distribution	$1.18 million	Robust growth in CosmoFarm distribution business
Owned Nutraceuticals/Pharmaceuticals and Manufacturing (CMO)	$0.87 million	Projected 25% revenue growth driven by new CMO agreements

The overall gross margin for the company reached a record 15.21% in Q3 2025, a 549 basis point improvement year-over-year, which signals that the channel mix is successfully tilting toward higher-margin sales like the U.S. Sky Premium Life launch and CMO work. Finance: draft 13-week cash view by Friday.

Cosmos Holdings Inc. (COSM) - Canvas Business Model: Customer Segments

You're looking at the customer base for Cosmos Holdings Inc. (COSM) as of late 2025, and the picture shows a clear pivot toward higher-margin, proprietary products, even as the foundational distribution business remains active globally.

The customer segments are quite diverse, reflecting the company's vertically integrated structure across distribution, manufacturing, and proprietary brands. The financial data from the third quarter of 2025 shows the overall revenue momentum, with Q3 2025 revenue hitting an all-time high of $17.11 million, up 38% from Q3 2024.

Here is a breakdown of the key customer groups Cosmos Holdings Inc. serves:

• Wholesale drug distributors and wholesalers globally.
• Retail pharmacies and hospital networks.
• Consumers seeking high-quality nutraceuticals (e.g., Sky Premium Life).
• Pharmaceutical and healthcare companies needing contract manufacturing.
• Patients utilizing the telehealth services.

The distribution arm, which serves the first two segments, still contributes meaningfully, though the focus is shifting. For the first quarter of 2025, the Wholesale logistics distribution segment contributed $1.18 million to gross profit. This business involves distributing branded generics and OTC medications through subsidiaries in Greece and the UK. The CosmoFarm distribution business is specifically noted as being supported by an expanding pharmacy network.

The consumer segment, driven by the proprietary nutraceutical brand, is a major growth area. The flagship brand, Sky Premium Life, has seen significant expansion, with the total SKU count now exceeding 150 products. The launch of NOOR Collagen in the U.S. market is projected to generate more than $12 million in annualized revenue alone, with an anticipated gross margin of approximately 75%. Furthermore, global expansion is evident, such as the distribution agreement signed in Oman, which included an initial purchase order of 42,000 Units of Sky Premium Life products.

The contract manufacturing segment is another high-margin focus. This activity, combined with owned nutraceuticals/pharmaceuticals, contributed $0.87 million to gross profit in Q1 2025. The ramp-up of the contract manufacturing division at Cana Laboratories ("Cana") was cited as a driver for the record Q3 2025 gross margin of 15.21%.

The telehealth segment is served through the acquisition of ZipDoctor, Inc., based in Texas, USA. Specific utilization or revenue data for this segment as of late 2025 wasn't explicitly broken out in the latest reports, but it represents a strategic entry point for the company.

Here's a look at the segment contributions to gross profit where data is available for Q1 2025, showing the relative weight before the full impact of the U.S. nutraceutical launch:

Customer Segment Focus Area	Q1 2025 Gross Profit Contribution	Notes
Wholesale logistics distribution	$1.18 million	Distribution of pharmaceuticals and OTC medications in EU/UK.
Owned nutraceuticals/pharmaceuticals and manufacturing	$0.87 million	Includes contract manufacturing and proprietary brands like Sky Premium Life.

The overall financial performance in the first nine months of 2025 shows total revenue of $45.57 million, with gross profit rising 76% year-over-year to $5.82 million. This margin expansion is directly tied to serving these higher-value segments.

For the telehealth segment, Cosmos Holdings Inc. has entered the space via the acquisition of ZipDoctor, Inc.. The company is also leveraging a $300 million financing facility to support growth initiatives, which includes accelerated product development and enhanced commercial initiatives.

Finance: draft 13-week cash view by Friday.

Cosmos Holdings Inc. (COSM) - Canvas Business Model: Cost Structure

You're looking at the cost side of the Cosmos Holdings Inc. (COSM) business as of late 2025. The company has been actively managing expenses while simultaneously investing in growth, which shows up clearly in the recent quarterly figures. Honestly, tracking these costs against revenue shifts is key to understanding their path to sustained profitability.

The cost structure is heavily influenced by the dual focus on wholesale logistics distribution and the higher-margin owned nutraceuticals/pharmaceuticals and manufacturing segments. For the first quarter of 2025 (Q1 2025), the revenue contribution from these segments was reported as:

• Wholesale logistics distribution: $1.18 million.
• Owned nutraceuticals/pharmaceuticals and manufacturing: $0.87 million.

We can calculate the Cost of Goods Sold (COGS) based on the reported Gross Profit and Revenue for the periods where data is available. For Q1 2025, revenue was $13.71 million and Gross Profit was $2.05 million, implying a COGS of $11.66 million. By the third quarter of 2025 (Q3 2025), with revenue at $17.11 million and Gross Profit at $2.60 million, the implied COGS rose to $14.51 million, reflecting the higher sales volume in that record quarter.

Operating expenses show a clear trend of cost discipline in early 2025, though they increased later in the year to support expansion. In Q1 2025, total operating expenses were $2.88 million, a decline of 9.05% from the prior year period's $3.17 million. This reduction was driven by specific internal initiatives.

The breakdown of those Q1 2025 operating expense reductions is telling:

• Salaries and wages saw a 17.34% reduction, driven by efficiency initiatives.
• Sales and marketing expenses declined by 83.78% due to a strategic cut in promotional spend.
• General and administrative expenses (G&A) decreased by 14.46% (adjusted for non-cash items).

However, by Q3 2025, the company was strategically increasing spending to fuel growth. Total operating expenses in Q3 2025 reached $4.42 million, up from $3.45 million in Q3 2024, reflecting investments in talent and scientific personnel. For the nine-month period ending September 30, 2025, total operating expenses were $11.11 million.

Regarding Research and Development (R&D), while specific expense figures aren't isolated in the latest reports, the company confirms active projects, such as the CCX0722 weight management solution entering its final development phase. These scientific personnel investments are embedded within the increased Q3 2025 operating expenses.

Finally, on the balance sheet side, the company's obligations are significant. As of the third quarter of 2025 (Q3 2025), total liabilities stood at $46.36 million. This increase from $35.65 million in Q2 2025 reflects the strategic utilization of the $300 million financing facility to support digital asset investments and working capital. While the specific dollar amount for debt servicing (interest expense) isn't itemized in the provided data, the liability figure itself dictates the scale of required servicing payments.

Here's a quick look at the key expense and liability figures we have for Cosmos Holdings Inc. as of late 2025:

Cost Component / Metric	Q1 2025 Amount	Q3 2025 Amount	Comparative Context
Implied COGS (Calculated)	$11.66 million (Based on $13.71M Rev, $2.05M GP)	$14.51 million (Based on $17.11M Rev, $2.60M GP)	COGS scales with revenue growth between Q1 and Q3.
Total Operating Expenses (OpEx)	$2.88 million	$4.42 million	Q1 OpEx down 9.05% YoY; Q3 OpEx reflects strategic hiring.
Salaries & Wages Impact	17.34% reduction	N/A	Key driver in Q1 2025 OpEx decrease.
G&A Expenses Impact	14.46% decrease (Adjusted)	N/A	Confirms G&A was defintely decreasing in Q1 2025.
Total Liabilities	N/A	$46.36 million	Reflects utilization of the $300 million financing facility.

Cosmos Holdings Inc. (COSM) - Canvas Business Model: Revenue Streams

Cosmos Health Inc. revenue streams are diversified across several core operational segments, reflecting its vertically integrated structure. The company reported a record quarter for Q3 2025, with revenue hitting $17.11 million, marking a 38% increase from $12.41 million in Q3 2024. The full-year 2025 revenue is projected to reach $68.4 million.

The key components driving this revenue include:

• Revenue from wholesale logistics distribution, specifically mentioning the CosmoFarm distribution business supported by higher volumes.
• Sales of proprietary nutraceutical brands, such as Sky Premium Life, which saw significant global expansion. The Sky Premium Life NOOR Collagen product alone is projected to generate over $12 million in annualized revenue from its U.S. launch.
• Contract manufacturing fees from Cana Laboratories, which is noted for its ramp-up and contribution to the stronger sales mix. Cana Laboratories is projected to generate over $10M+ in annual gross profit.
• Sales of generic and branded over-the-counter (OTC) pharmaceuticals, which the company distributes to retail pharmacies and wholesale distributors.

The performance in Q3 2025 also showed a gross margin expansion to a record 15.21%, up from 9.72% a year earlier. This margin improvement is attributed to a stronger sales mix, including increased contributions from higher-margin nutraceuticals and contract manufacturing divisions.

Here's a look at the recent financial performance metrics:

Metric	Value	Period/Context
Q3 2025 Revenue	$17.11 million	Quarter ended September 30, 2025
Projected FY 2025 Revenue	$68.4 million	Full Year 2025 Projection
Revenue (Nine Months Ended Sep 30, 2025)	$45.57 million	Nine-month period
Annual Revenue	$54.43 million	FY 2024
Q3 2025 Gross Profit	$2.60 million	Quarter ended September 30, 2025
Q3 2025 Gross Margin	15.21%	Quarter ended September 30, 2025
Gross Margin (Nine Months Ended Sep 30, 2025)	12.76%	Nine-month period
Projected Annual Gross Profit from Cana Labs	$10M+	Annual projection
Projected Annualized Revenue from Sky Premium Life NOOR Collagen	Over $12 million	U.S. launch projection

The company's gross margin for the nine-month period ending September 30, 2025, was 12.76%, up from 8.23% in the prior-year period. To be fair, the high projection for the NOOR Collagen revenue suggests a strong focus on high-margin proprietary products, with an expected gross margin of approximately 75% for those U.S. nutraceutical sales. Finance: draft 13-week cash view by Friday.